In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
This phenomenon is predominantly caused by cobalamin release during hepatic cytolysis and/or decreased cobalamin clearance by the affected liver
Nevertheless, the classic antidepressants used in clinical practice today are not always effective for the different types of depression and suffer from problems such as low response rates and delayed effects [11]
This deficiency can lead to megaloblastic anemia, where the body produces large, abnormal red blood cells that cannot function effectively, resulting in symptoms such as fatigue, weakness, and neurological issues
They are often grouped together only because both appear frequently in preclinical tissue-repair research
